Leading Scientists and Cardiologists Gather at International Conference in Riga

Bringing together healthcare professionals from 13 countries, Latvia’s largest pharmaceutical company, A/S "Grindeks," hosted an international conference where leading scientists and cardiologists presented clinical research data and exchanged views and experiences in treating cardiovascular diseases.

For over 35 years, A/S "Grindeks" has offered an original product for treating cardiovascular diseases, widely used in the Baltics and CIS countries, which has gained significant recognition among doctors and patients alike. The product is currently registered in 40 countries and has recently expanded into European markets, including Poland, Bulgaria, Slovakia, and Slovenia.

The conference, organized in collaboration with the Latvian Society of Cardiology and the Latvian Hypertension and Atherosclerosis Society, was opened by the Chairman of the Board of A/S "Grindeks," PhD Juris Hmeļņickis, and the President of the Latvian Academy of Sciences, academician Professor Ivars Kalviņš, who emphasized that Latvia has many talented individuals not only in sports and culture but also in pharmacy and medicine.

The first presentation was delivered by the President of the Latvian Society of Cardiology, MD, PhD Andrejs Ērglis, who discussed heart metabolism and the significant changes that occur under ischemic conditions. He also shared interesting facts, such as the heart beating approximately 2.5 to 4 billion times over a lifetime, making it the organ that consumes the most energy by pumping 10 tons of blood throughout the body.

Professor Maija Dambrova, Senior Researcher at the Latvian Institute of Organic Synthesis and Professor at Riga Stradiņš University’s Faculty of Pharmacy, introduced the pharmacological effects of Latvia's original product for cardiovascular disease treatment, highlighting its cardiometabolic aspects. Meanwhile, Vilnis Dzērve, Director of the University of Latvia's Institute of Cardiology and Regenerative Medicine, presented the clinical trial results of this medication for chronic heart failure and stable angina. This topic was further expanded by Professor Kārlis Trušinskis from the Latvian Cardiology Center at Pauls Stradiņš Clinical University Hospital, who demonstrated the first positive results from the latest observations. Next, Professor Ilze Konrāde, an endocrinologist from Riga Stradiņš University, presented research findings related specifically to diabetic patients.

In the second part of the conference, leading cardiologists from Lithuania, Georgia, Bulgaria, and Moldova presented the results of their research.

"Conferences like these are crucial for healthcare professionals, providing an opportunity to exchange knowledge, share experiences, and discuss research results. We are very proud to bring together specialists from near and far, who value the work of Latvian scientists and carry the name of 'Grindeks' worldwide," said Kirovs Lipmans, Chairman of the Supervisory Board of A/S "Grindeks."

 

About the Grindeks Group

Grindeks is an international pharmaceutical group that ensures the full product lifecycle—research, development, pharmacovigilance, production, and sale of original products, generics, and active pharmaceutical ingredients. As of 2024, the group exports its products to over 100 countries. Grindeks focuses on cardiology, central nervous system, oncology, diabetes, dermatology, and active pharmaceutical ingredients. The subsidiary Kalceks specializes in medications for hospital segments and ophthalmology. All products are manufactured to meet the highest global safety and quality standards. The Grindeks Group employs over 1,380 people and had a turnover of 257.9 million euros in 2022.